Feverfew herb grows widely across Europe and North America. The leaves of feverfew have been historically used for the therapy of fever and more recently migraine headaches. For centuries, healers relied on the feathery green leaves of feverfew (Tanacetum parthenium) to treat headaches, stomach upset, rheumatoid arthritis, and menstrual problems. The bright yellow and white blossoms of this flower, which grows wild throughout Europe and South America, emit a powerful aroma that was once thought to purify the air and prevent disease. Feverfew has also long been used in gardens to repel bees and various insects. And as its common name suggests, it was once popular for reducing fever. The herb was somewhat forgotten, however, until the late 1970s. That's when migraine sufferers started talking about feverfew's potential to ward off these often debilitating headaches. Buy Feverfew herb here.

What's in Feverfew herb?
Feverfew herb contains a range of compounds known as sesquiterpene lactones. Over 85% of these are a compound called parthenolide. The active ingredient in feverfew, parthenolide, specifically binds to and inhibits a protein which plays a role in the body's inflammatory process. Fever is part of the body's inflammatory response, and inflammation contributes to a range of ailments--including migraines. Parthenolide helps prevent excessive clumping of platelets and inhibits the release of certain inflammatory chemicals. Feverfew's active ingredient parthenolide specifically binds to and inhibits the protein IKK-beta, which plays a role in the body's inflammatory process. Fever is part of the body's inflammatory response, and inflammation contributes to a range of ailments--including migraines.
   The routine dosage of feverfew is 100 to 300 mg up to four times a day, 0.2 to 0.4% parthenolide.
   Results of studies with feverfew in the therapy or prevention of migraine headaches have not been consistent.

Enzymatic Therapy - Feverfew, 30 Capsules
Feverfew herb is stabilized and standardized to guarantee 600 mcg of Parthenolide per capsule (verified by HPLC).  Parthenolide is feverfew's most beneficial compound.  Feverfew is made from feverfew flowers and leaves harvested when the plant is richest in Parthenolide content.  Just one capsule daily provides the maximum value feverfew has to offer.

Feverfew herb Migraine Remedy
German researchers report that feverfew extract has potential for migraine headache help. The researchers conducted a study with 170 migraine patients. At the beginning of the trial, migraine frequency was approximately five attacks over a 4-week period. The subjects were then randomly assigned to treatment with feverfew or placebo three times a day for up to 16 weeks. In the feverfew treatment group, migraine frequency declined by two attacks per month. In the placebo patients, the corresponding decrease was only one per month. Analysis of responder rates revealed that feverfew was 3 times more effective than placebo.

Feverfew herb summary
Feverfew is helpful to some migraine sufferers although a review of published studies does not support the view that feverfew is consistently effective.
   The dosage is about 100 to 150 mg of the freeze-dried powdered herb, containing at least 0.4% parthenolide, taken twice a day. Benefits may be noticed within a month or two. Exercise, B vitamins, and magnesium supplements may also help. Some migraine sufferers also notice benefits from a low gluten diet.

Feverfew herb studies
Cochrane Database Syst Rev. 2004;(1):CD002286. Department of Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, 25 Victoria Park Road, Exeter, Devon, UK, EX2 4NT.
Feverfew (Tanacetum parthenium L.) extract is a herbal remedy used for preventing attacks of migraine. To systematically review the evidence from double-blind randomised controlled trials assessing the clinical efficacy and safety of feverfew versus placebo for preventing migraine. Trials using clinical outcome measures were included. Trials focusing exclusively on physiological parameters were excluded. There were no restrictions regarding the language of publication. Data on patients, interventions, methods, outcome measures, results and adverse events were extracted systematically.  Two reviewers independently selected studies, assessed methodological quality and extracted data. Disagreements concerning evaluation of individual trials were resolved through discussion. MAIN RESULTS: Five trials (343 patients) met the inclusion criteria. Results from these trials were mixed and did not convincingly establish that feverfew is efficacious for preventing migraine. Only mild and transient adverse events were reported in the included trials. There is insufficient evidence from randomised, double-blind trials to suggest an effect of feverfew over and above placebo for preventing migraine. It appears from the data reviewed that feverfew presents no major safety problems.

back to index yohimbe bark

feverfew herb studies feverfew and migraine feverfew and headache